Clinical Trial Update: Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an anti-cancer immunotherapy with standard neoadjuvant treatment in WT1-positive primary invasive breast cancer; study terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neoplastic Diseases

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: TERMINATED | Results posted: 2017-05-25